Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 5 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 3 Neoplasm Metastasis 2 Triple Negative Breast Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Myeloproliferative Disorders 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1 Hematologic Neoplasms 1 Gastrointestinal Stromal Tumors 1 Breast Neoplasms 1 Blast Crisis 1

Interventions

Trastuzumab 209 Paclitaxel 187 Fulvestrant 161 Capecitabine 150 Docetaxel 136 Letrozole 127 exemestane 92 palbociclib 76 Anastrozole 75 Cyclophosphamide 71 Lapatinib 69 Gemcitabine 66 Bevacizumab 66 pertuzumab 61 pembrolizumab 60 ribociclib 59 Carboplatin 59 abemaciclib 53 eribulin 48 Doxorubicin 45 Vinorelbine 41 Everolimus 41 Ado-Trastuzumab Emtansine 41 Tamoxifen 40 130-nm albumin-bound paclitaxel 34 Injections 31 trastuzumab deruxtecan 30 Albumin-Bound Paclitaxel 26 olaparib 24 Alpelisib 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Breast Neoplasms × STA 9090 × Clear all

NCT01677455 2015-11-05

Enchant

Synta Pharmaceuticals Corp.

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡